AbbVie has entered a partnership and option-to-license agreement with Xilio for tumour-activated, antibody-based ...

The US Food and Drug Administration (FDA) has approved SpringWorks Therapeutics’ Gomekli (mirdametinib) to treat ...

The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

Lundbeck has received the US FDA fast track designation for amlenetug, a potential treatment for multiple system atrophy (MSA ...

GlobalData’s Revati Tatake discussed key trends in biopharma which are set to have an impact in 2025 and beyond.

Trump's tariffs will not only impact sponsors, but higher costs will ripple down the clinical trial supply chain in the US.

Travere’s stock price climbed by 14% following the announcement it will seek an FDA label expansion for Filspari.

EC has granted marketing authorisation to BridgeBio Pharma’s acoramidis under the Beyonttra brand name for treating ATTR-CM.

Health Canada has approved MSD’s anti-programmed cell death protein 1 (PD-1) therapy Keytruda for treating adults with ...

Eli Lilly is paying up to $630m for a Phase I MASH candidate from OliX Pharmaceuticals, diversifying its pipeline with an RNA ...

Bio-Thera Solutions has signed an exclusive licence and commercialisation agreement with Intas Pharmaceuticals for BAT2506 in ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...